Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical experience with efanesoctocog alfa in patients with uncover needs on emicizumab

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCarlos Pisón HerreroMJMiren Gabilondo JalónMMMaria Jose Paloma Mora

Discussion

Loading...

Member takes

Overview

Case data shows improvements in hemostatic control and reduces pain in patients with hemophilia A, suggesting efanesoctocog alfa is beneficial for surgical complications.

Key Points

  • This research evaluates the efficacy of efanesoctocog alfa for patients with hemophilia A who have unmet needs under emicizumab.
  • Data from four adult male hemophilia A patients were analyzed after switching from emicizumab to efanesoctocog alfa.
  • Patients received efanesoctocog alfa at 50 IU/kg weekly after a washout period from emicizumab.
  • Joint control and postoperative hemostasis were monitored post-treatment.
  • The treatment was safe with no observed thrombotic events or inhibitors.
  • Factor VIII trough levels were maintained above 10%, with peak levels between 80–130%.
  • Patients reported reduced pain, requiring fewer analgesics, and no joint hemorrhages occurred during follow-up.

Cite This Study

Herrero et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbc1https://doi.org/10.1182/blood-2025-6624
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Tailored prophylaxis in severe hemophilia A: Real-world experience with efanesoctocog alfa2025
  2. 2Successful surgical management in severe hemophilia A patients using efanesoctocog alfa: A two-case experience undergoing orthopedic surgery2025
  3. 3Unmet needs despite standard-of-care prophylaxis in Hemophilia A: improved outcomes after switching to Efanesoctocog Alfa2026
  4. 4Perioperative use of efanesoctocog alfa in Hemophilia A: A dual-center real-world study2025
  5. 5Comprehensive Assessment of the Transition to Efanesoctocog Alfa Prophylaxis in a Paediatric Haemophilia A Cohort2026